Catalyst

Slingshot members are tracking this event:

Bluebird Bio (BLUE) to present interim data from Starbeam Study of Lenti-D for its effectiveness in treating cerebral adrenoleukodystrophy at the American Academy of Neurology (AAN) 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BLUE

100%

Additional Information

Additional Relevant Details Our Lenti-D product candidate has the potential to stabilize or prevent progression of CALD with one treatment. Our approach involves inserting a functional copy of the ABCD1 gene in the patient’s hematopoietic stem cells outside the body (ex vivo), then re-introducing the genetically modified cells into the patient.
http://www.bluebirdb...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 20, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Lenti-d, Phase 2/3 Study, Cerebral Adrenoleukodystrophy, Interim Clinical Data, Neurology Conference, Allo-hsct, Hsct